Cristina Bugés

955 total citations
21 papers, 693 citations indexed

About

Cristina Bugés is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Cristina Bugés has authored 21 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Cristina Bugés's work include Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Research Studies (5 papers). Cristina Bugés is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Research Studies (5 papers). Cristina Bugés collaborates with scholars based in Spain, Italy and United Kingdom. Cristina Bugés's co-authors include Laura Layos, José Luís Zamora Manzano, Eva Martinez‐Balibrea, Anna Martínez‐Cardús, Sara Bystrup, Vicenç Ruiz de Porras, Albert Abad, Laia Vilà, María de los Llanos Gil and Cátia Moutinho and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Cristina Bugés

21 papers receiving 684 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cristina Bugés Spain	9	387	354	153	113	87	21	693
Laura Layos Spain	13	485 1.3×	564 1.6×	211 1.4×	115 1.0×	104 1.2×	30	973
Yegang Ma China	15	583 1.5×	185 0.5×	169 1.1×	81 0.7×	133 1.5×	50	777
Vineshkumar Thidil Puliyappadamba United States	14	391 1.0×	161 0.5×	136 0.9×	87 0.8×	40 0.5×	15	643
Martine Schmitz Luxembourg	10	415 1.1×	165 0.5×	226 1.5×	102 0.9×	46 0.5×	19	620
Sühendan Ekmekçioğlu United States	15	403 1.0×	278 0.8×	139 0.9×	110 1.0×	35 0.4×	22	839
Jamunarani Veeraraghavan United States	17	393 1.0×	346 1.0×	258 1.7×	192 1.7×	32 0.4×	36	880
Teng Yu China	18	496 1.3×	177 0.5×	139 0.9×	99 0.9×	132 1.5×	47	906
Poulami Khan India	11	334 0.9×	210 0.6×	143 0.9×	40 0.4×	38 0.4×	15	542
Jing‐Wen Bai China	17	572 1.5×	308 0.9×	269 1.8×	159 1.4×	70 0.8×	39	1.0k
Liuxing Wang China	18	629 1.6×	210 0.6×	402 2.6×	104 0.9×	49 0.6×	47	905

Countries citing papers authored by Cristina Bugés

Since Specialization

Citations

This map shows the geographic impact of Cristina Bugés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cristina Bugés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cristina Bugés more than expected).

Fields of papers citing papers by Cristina Bugés

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cristina Bugés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cristina Bugés. The network helps show where Cristina Bugés may publish in the future.

Co-authorship network of co-authors of Cristina Bugés

This figure shows the co-authorship network connecting the top 25 collaborators of Cristina Bugés. A scholar is included among the top collaborators of Cristina Bugés based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cristina Bugés. Cristina Bugés is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pous, Anna, et al.. (2023). HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies. International Journal of Molecular Sciences. 24(14). 11403–11403. 21 indexed citations

Sun, Chen, et al.. (2022). Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going. Clinical Colorectal Cancer. 21(2). 71–79. 4 indexed citations

Alsina, María, Mariano Ponz‐Sarvisé, Marta González, et al.. (2021). MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).. Journal of Clinical Oncology. 39(15_suppl). TPS4155–TPS4155. 3 indexed citations

Hierro, Cinta, J.P. Suárez Fernández, Cristina Bugés, et al.. (2020). Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. Drugs in Context. 9. 1–13. 5 indexed citations

Laquente, Berta, Teresa Macarulla, Cristina Bugés, et al.. (2020). Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice. BMC Palliative Care. 19(1). 103–103. 11 indexed citations

Azuara, Daniel, David Páez, E. Falcó, et al.. (2019). Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. Annals of Oncology. 30(5). 796–803. 22 indexed citations

Porras, Vicenç Ruiz de, Sara Bystrup, Eva Musulén, et al.. (2019). Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients. Cancers. 11(10). 1540–1540. 19 indexed citations

Salazar, Ramón, Daniel Azuara, José María Viéitez, et al.. (2017). ULTRA clinical trial: Prospective comparative clinical outcome analysis of three different RAS/BRAF sensitivity mutational cut-offs. A Phase II study of the Spanish TTD Group. Annals of Oncology. 28. v185–v186. 1 indexed citations

Manzano, José Luís Zamora, Laura Layos, Cristina Bugés, et al.. (2016). Resistant mechanisms to BRAF inhibitors in melanoma. Annals of Translational Medicine. 4(12). 237–237. 177 indexed citations

10.

Porras, Vicenç Ruiz de, Sara Bystrup, Anna Martínez‐Cardús, et al.. (2016). Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway. Scientific Reports. 6(1). 24675–24675. 113 indexed citations

11.

Martinez‐Balibrea, Eva, Anna Martínez‐Cardús, Alba Ginés, et al.. (2015). Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance. Molecular Cancer Therapeutics. 14(8). 1767–1776. 261 indexed citations

12.

Carcereny, Enric, Anna Estival, Teresa Morán, et al.. (2015). Prevalence of ROS1 translocation, HER2, and BRAF mutations in a cohort of advanced Non-Small Cell Lung Cancer (NSCLC) patients (p) triple negative (TN).. Journal of Clinical Oncology. 33(15_suppl). e22139–e22139. 2 indexed citations

13.

Bugés, Cristina, Enric Carcereny, Teresa Morán, et al.. (2014). Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient. Clinical Lung Cancer. 16(2). e1–e3. 1 indexed citations

14.

Villà, S., et al.. (2013). Patterns of relapse in glioblastoma after neoadjuvancy and radiation therapy. Reports of Practical Oncology & Radiotherapy. 18. S195–S195. 1 indexed citations

15.

Balañá, Carmen, María Ángeles Vaz Salgado, M.J. Molina-Garrido, et al.. (2013). Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. Clinical & Translational Oncology. 16(3). 273–279. 12 indexed citations

16.

Goel, Sanjay, Teresa Morán, Santiago Viteri, et al.. (2012). Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3093–3093. 2 indexed citations

17.

Rosell, Rafael, Miguel Ángel Molina‐Vila, Miquel Tarón, et al.. (2012). EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.. Journal of Clinical Oncology. 30(15_suppl). 7522–7522. 22 indexed citations

18.

Bugés, Cristina, Rafael Rosell, A. Vergnenègre, et al.. (2012). Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study.. Journal of Clinical Oncology. 30(15_suppl). 7542–7542. 2 indexed citations

19.

Carcereny, Enric, Miquel Tarón, Cristina Queralt, et al.. (2012). Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.. Journal of Clinical Oncology. 30(15_suppl). 7540–7540. 3 indexed citations

20.

Carcereny, Enric, Matias Molina, José Javier Sánchez, et al.. (2011). Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations.. Journal of Clinical Oncology. 29(15_suppl). 7588–7588. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact